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Abstract
Background: Chromosomal instability (CIN) is the most prevalent type of genomic instability in
gastric tumours, but its role in malignant transformation of the gastric mucosa is still obscure. In
the present study, we set out to study whether two morphologically distinct categories of gastric
cancer precursor lesions, i.e. intestinal-type and pyloric gland adenomas, would carry different
patterns of DNA copy number changes, possibly reflecting distinct genetic pathways of gastric
carcinogenesis in these two adenoma types.
Results: Using a 5K BAC array CGH platform, we showed that the most common aberrations
shared by the 11 intestinal-type and 10 pyloric gland adenomas were gains of chromosomes 9
(29%), 11q (29%) and 20 (33%), and losses of chromosomes 13q (48%), 6(48%), 5(43%) and 10
(33%). The most frequent aberrations in intestinal-type gastric adenoma were gains on 11q, 9q and
8, and losses on chromosomes 5q, 6, 10 and 13, whereas in pyloric gland gastric adenomas these
were gains on chromosome 20 and losses on 5q and 6. However, no significant differences were
observed between the two adenoma types.
Conclusion: The results suggest that gains on chromosomes 8, 9q, 11q and 20, and losses on
chromosomes 5q, 6, 10 and 13, likely represent early events in gastric carcinogenesis. The
phenotypical entities, intestinal-type and pyloric gland adenomas, however, do not differ
significantly (P = 0.8) at the level of DNA copy number changes.
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Gastric cancer is the second most frequent malignancy
worldwide and the prognosis of this malignancy remains
very poor [1]. Gastric cancer incidence and mortality rates
differ between different countries within the European
Union [2]. In the Netherlands it ranks fifth as a cause of
cancer death, with approximately 2,200 new cases each
year [3]. Surgery with curative intent is the treatment of
choice in advanced cases of gastric cancer, whereas local
endoscopic mucosectomy can be curative in early gastric
cancer. Detection and removal of gastric neoplasias in an
early or even premalignant state will contribute to reduce
death due to gastric cancer. To achieve this goal, better
tests for early detection of gastric cancer are needed, and
an improved understanding of the biology of gastric can-
cer progression is crucial in this respect.
According to the Correa model, pathogenesis of intesti-
nal-type gastric adenocarcinoma follows a pathway of
chronic active gastritis due to Helicobacter pylori infection,
leading to mucosal atrophy, intestinal metaplasia fol-
lowed by intraepithelial neoplasia and finally invasive
adenocarcinoma [4]. Genetic characterization of tissue
samples in intraepithelial neoplasia stage would substan-
tially contribute to our understanding of the molecular
pathogenesis of gastric cancer. However, these lesions are
only rarely detected, possibly due to rapid progression
through this stage towards cancer, and are usually present
only in parts of biopsy specimens, hampering genomic
analysis of these lesions. Analysis of alternative precursor
lesions could therefore, at least partly, be a substitute.
Development of gastric cancer through an adenoma stage,
although less common, is such alternative route. These
adenomas are occasionally detected during gastroscopy
and present as large lesions that histologically show intra-
epithelial neoplasia, which makes them suitable for
genomic analysis. Gastric adenomas have a direct malig-
nant potential and account for approximately 20% of all
epithelial polyps [5,6]. Gastric adenomas can have a clas-
sic tubular, tubulovillous, or villous morphology with a
predominantly intestinal-type epithelium, but can also
appear as pyloric gland adenomas [6]. Pyloric gland ade-
nomas arise from deep mucoid glands in the stomach and
are strongly positive for mucin 6 [7,8]. A substantial
number of gastric adenomas already show progression to
adenocarcinoma. On first diagnosis around 30–40% of all
pyloric gland adenomas already show a focus of carci-
noma [9,10]. For intestinal-type adenomas this number is
lower and varies from 28,5% for villous adenomas and
29.4% for tubulovillous type adenomas to only 5.4% in
the tubular adenomas [11]. Both adenocarcinomas, ex
intestinal-type adenomas and ex pyloric gland adenomas,
show glandular structures, in contrast to diffuse type gas-
tric cancer.
A key feature in the pathogenesis of most gastric cancers,
as in many other solid cancers, is chromosomal instabil-
ity, resulting in gains and losses of parts or even whole
chromosomes [12]. These chromosomal changes can be
analyzed by comparative genomic hybridization (CGH).
Several previous studies have detected genetic alterations
in gastric adenomas using this technique, being gains on
chromosome 7q, 8q, 13q, 20q, and losses on chromo-
some 4p, 5q, 9p 17p and 18q [13-16]. Although uncom-
mon and only observed in adenomas with high grade
intraepithelial neoplasia, high level amplifications have
been detected on chromosomes 7q, 8p, 13q, 17q and 20q
[13-16]. In gastric adenocarcinomas, consistently
described chromosomal aberrations are gains on chromo-
some 3q, 7p, 7q, 8q, 13q, 17q and 20q and losses on chro-
mosome 4q, 5q, 6q, 9p, 17p and 18q. High level
amplifications have been repeatedly detected on 7q, 8p,
8q, 17q, 19q and 20q [14,17-23]. Yet, chromosomal aber-
rations, or DNA copy number changes, are not uniform in
gastric cancer [24]. Subgroups with different patterns of
DNA copy number alterations can be recognized, which
have been shown to be associated with clinical outcome
as well [25].
In the present study, we set out to study whether two mor-
phologically distinct categories of gastric cancer precursor
lesions, i.e. intestinal-type and pyloric gland adenomas,
would carry different patterns of DNA copy number
changes, possibly reflecting distinct genetic pathways of
gastric carcinogenesis in the two adenoma types.
Results
DNA copy number changes were observed in 10 out of 11
intestinal-type adenomas and 9 out of 10 pyloric gland
adenomas. The mean number of chromosomal events,
defined as gains and losses, per tumour was 6.0 (range 0–
18), including 2.9 (range 0–14) gains and 3.0 (range 0–7)
losses. In intestinal-type adenomas, the mean number of
chromosomal events per tumour was 6.5 (range 0–18) of
which 3.4 (range 0–14) gains and 3.1 (range 0–7) losses,
and in the pyloric gland adenomas the mean numbers
were 5.4 (range 0–9), 2.4 (range 0–7) and 3.0 (range 0–7)
respectively.
In the intestinal-type gastric adenomas, the most com-
mon aberrations observed were gains on chromosomes 8,
9q and 11q, and losses on chromosomes 5q, 6, 10 and 13.
In four adenomas (36.4%), gain of chromosome 11q23.3
was observed with a common region of overlap of 2.6 Mb.
Gain of chromosome 9q was observed in four adenomas
(36.4%) with a 12.6 Mb common region of overlap
located on chromosome 9q33.1-q34.13. Gain of chromo-
some 8 was observed in three adenomas (31%), two of
which adenomas showed gain of whole chromosome 8,
and the third adenoma showed a gain of chromosome 8p-Page 2 of 10
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8q24.11-qter. In addition, gains were observed on chro-
mosomes 1, 3, 6p, 7, 11p, 12p, 13q, 16, 17, 19, 20 and
22q. No amplifications were seen in the intestinal-type
adenomas.
Deletions on chromosome 13 were observed in seven
intestinal-type adenomas (64%). Of these, five showed a
11.9 Mb deletion of chromosome 13q21.2-21.33 with an
additional 7.7 Mb deletion on chromosome 13q31.1-
31.3. The other two adenomas showed a 16.6 Mb deletion
of 13q14.3-31. A deletion on chromosome 6 was
observed in six adenomas (55%), with an overlapping
region of 68.9 Mb located on 6cen-q22.1. A deletion of
chromosome 5q was observed in four adenomas (36%)
with a common region of overlap located on chromo-
some 5q22.1-q23.2. In addition, a deletion of whole
chromosome 10 was observed in four adenomas (36%).
Other losses observed in intestinal-type adenomas were
located on chromosomes 8q, 9p, 10, 12q, 20q and 21. An
overview of all DNA copy number aberrations of the intes-
tinal-type adenomas is shown in Table 1.
The most frequent aberration observed in pyloric gland
adenomas were gains on chromosome 20 and losses on
chromosomes 5q and 6. Gains on chromosome 20 were
seen in four adenomas (40%). Three adenomas showed a
9.8 Mb gain of chromosome 20q13.12-q13.33, and gain
of whole chromosome 20 was observed in the other ade-
noma. In addition, gains were seen on chromosomes 1,
3q, 5q, 7, 9q, 11q, 12q, 13q, 15q, 17 and 22q. One pyloric
gland adenoma showed amplifications, located on
12q13.2-q21.1 and 20q13.3-q13.33.
Five pyloric gland adenomas (50%) showed loss of chro-
mosome 5q, two of which had lost a whole chromosome
arm, while two adenomas showed a 22.4 Mb deletion of
5q11.2-q13.3 and one adenoma a 40.3 Mb deletion of
5q21.1-q31.2. Loss of chromosome 6 was observed in
four pyloric gland adenomas (40%), three of which
showed a complete loss of 6q and one adenoma showed
a 51.2 Mb deletion of 6p21.1-q16.3. Other chromosomal
losses were observed on chromosomes 1p, 2q, 4, 9p, 10,
12q 13q, 14q, 16, 18q, 20q, and 21. An overview of DNA
copy number aberrations of the pyloric gland adenomas
is shown in Table 2.
The most common aberrations shared by both intestinal-
type and pyloric gland adenomas were gain of chromo-
some 9q (29%), 11q (29%), and 20q (33%) and loss of
chromosome 5 (43%), 6 (48%), 10 (33%) and 13q
(48%). By comparing intestinal-type and pyloric gland
adenomas, CGH Multiarray revealed eight clones to be
significantly different, six of which were located at chro-
mosome 6q14-q21 (p = 0.02 to 0.05) and two clones on
chromosome 9p22-p23 (p = 0.02 and 0.04, respectively)
(Figure 1). No genes located in the regions covered by
these clones have been known to be involved in cancer
related biological processes. Yet, CGH Multiarray Region,
after correction for multiplicity, yielded a false discovery
rate (FDR) of 1 for all these regions, indicating no signifi-
cant differences between the two different types of adeno-
mas at the chromosomal level. Unsupervised hierarchical
cluster analysis yielded 2 clusters. No significant associa-
tions were found here (p = 0.8).
Discussion
Given the heterogeneous phenotype of gastric cancer, the
present study primarily aimed to compare copy number
changes between intestinal-type adenomas and pyloric
gland adenomas, in order to find leads towards genetic
pathways involved in the pathogenesis of gastric cancer.
Adenoma-to-carcinoma progression is observed in 30–
40% of the pyloric gland adenomas and in approximately
5–30% of the intestinal-type adenomas (varying from
about 5% in tubular adenomas to almost 30% for tubu-
lovillous and villous adenomas) [9-11], indicating the
direct malignant potential of these two adenoma types
and making gastric adenomas a suitable model for detect-
ing early events in gastric carcinogenesis.
Pyloric gland adenomas constitute a recently recognized
entity [8,26]. To the best of our knowledge, this type of
adenomas has never been analyzed by array CGH before.
The mean number of events in this type of adenoma was
5.4 (0–9), with 2.4 (0–7) gains and 3 (0–7) losses. This is
comparable with the mean number of aberrations in
intestinal-type adenomas (6.5 (0–18), 3.4 (0–14) and 3.1
(0–7) respectively). In pyloric gland adenomas, frequent
events were gain on chromosome 20 and losses on chro-
mosomes 5q and 6, while intestinal-type adenomas
mainly showed gain on chromosomes 8, 9q, and 11q, and
losses on chromosomes 5q, 6, 10 and 13. In the present
study, gain of chromosome 7 was less common than
found previously [16]. Although these frequently altered
regions differ between the two types of adenomas, hierar-
chical cluster analyses did not separate the groups. In
addition, CGH Multiarray Region did not reveal any sig-
nificant differences after correction for multiple compari-
sons. This lack of statistically significant differences could
be due to the limited sample size combined with the fact
that in general, adenomas show little chromosomal aber-
rations. On the other hand, it could simply be that these
morphologically different entities do not differ in terms of
chromosomal gains and losses. Finding no significant dif-
ferences at the chromosomal level does not preclude other
genetic and biological differences such as mutation or
promoter methylation status of specific genes.Page 3 of 10
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Chromosomal aberrations Flanking clones
Tumour ID Gains Losses Segment size (Mb) Start End
1 1p-p36.11 26.68 RP11-465B22 RP1-159A19
5q13.2-q23.2 55.26 RP11-115I6 CTB-1054G2
6p21.33-p21.1 13.78 RP11-346K8 RP11-227E22
6p21.1-q16.1 52.05 RP11-89I17 RP3-393D12
9q33.1-34.2 17.32 RP11-27I1 RP11-417A4
11q23.3 4.80 RP11-4N9 RP11-730K11
13q21.1-q31.3 39.63 RP11-200F15 RP11-62D23
2 1p-1p33 46.90 RP11-465B22 RP11-330M19
6p21.33-p21.1 14.12 RP11-346K8 RP11-121G20
6p21.1-q16.2 54.91 RP11-554O14 RP11-79G15
8p-q22.3 105.67 GS1-77L23 RP11-200A13
8q24.11-qter 28.65 RP11-278L8 RP5-1056B24
9q33.1-q34.2 13.63 RP11-85O21 RP11-417A4
11p11.2-q13.5 31.69 RP11-58K22 RP11-30J7
11q23.3 2.62 RP11-4N9 RP11-62A14
12q13.11-q14.1 10.57 RP11-493L12 RP11-571M6
13q21.1-q21.33 18.24 RP11-200F15 RP11-335N6
13q31.1-q31.3 12.49 RP11-533P8 RP11-62D23
16p13.3-q21 57.26 RP11-243K18 RP11-405F3
16q21-q22.1 5.97 RP11-105C20 RP11-298C15
16q22.1-q24.3 22.46 RP11-63M22 CTC-240G10
17 81.24 GS1-68F18 RP11-567O16
19 61.01 CTB-1031C16 GS1-1129C9
20q11.21-q11.23 5.09 RP3-324O17 RP5-977B1
20q13.12-qter 19.60 RP1-138B7 CTB81F12
3 - -
4 6p21.1 3.32 RP11-79J5 RP11-121G20
6p12.3-q22.1 76.38 RP11-79G12 RP11-59D10
7 156.89 RP11-510K8 CTB-3K23
8q22.3-q23.3 9.69 RP11-142M8 RP11-261F23
9q33.1-q34.13 12.58 RP11-55P21 RP11-83N9
11q23.3 3.04 RP11-4N9 RP11-8K10
13q21.2-q21.33 17.05 RP11-240M20 RP11-77P3
13q31.1-q31.3 11.68 RP11-400M8 RP11-100A3
16q23.2-q24.3 8.92 RP11-303E16 RP4-597G12
20p-q13.2 53.40 CTB-106I1 RP5-1162C3
20q13.31-qter 8.06 RP5-1167H4 CTB-81F12
22q 33.72 XX-P8708 CTB-99K24
5 12q24.31-qter 11.75 RP11-322N7 RP11-1K22
6 3 193.37 RP11-299N3 RP11-279P10
6cen-q24.1 88.49 RP11-91E17 RP11-86O4
7 156.09 RP11-510K8 RP11-518I12
8 144.26 RP11-91J19 RP5-1118A7
13q21.1-q21.33 11.86 RP11-640E11 RP11-452P23
13q31.1-q31.3 9.62 RP11-400M8 RP11-306O1
20q13.2-q13.31 1.41 RP11-212M6 RP4-586J11
7 5q21.1-qter 80.52 CTC-1564E20 RP11-281O15
10 132.19 RP11-29A19 RP11-45A17
13q21.33-31.1 8.76 RP11-209P2 RP11-470M1Page 4 of 10
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events in the stepwise process of accumulating changes
which may cause progression of adenoma to carcinoma.
As expected, the mean number of chromosomal events
was lower in adenomas compared to the carcinomas
[13,14,27]. Moreover, high level amplifications are
uncommon in adenomas, while carcinomas frequently
show high level amplifications [13,16].
The aberrations found in both intestinal-type and pyloric
gland adenomas, such as losses on chromosome 5q, are
also frequently detected in gastric carcinomas [15,19,28].
Previous CGH results showed a significantly higher
number of chromosome 5q losses in intestinal-type carci-
noma compared to diffuse type carcinoma [29]. Chromo-
some 6, also lost in both types of adenomas, frequently is
deleted in gastric carcinomas as determined by LOH stud-
ies [30,31]. Moreover, chromosome 6q deletion has been
reported to be involved in an early stage of gastric carcino-
genesis, since chromosome 6q deletions are frequently
detected in early gastric cancer and also in intestinal meta-
plasia [31,32]. Losses of chromosomes 10 and 13 have
been previously observed in adenomas at lower frequen-
cies. In gastric carcinomas, both gains and losses of chro-
mosome 10 and 13 have been observed by previous CGH
studies [15,19,21,33]. Chromosome 10 harbors the onco-
gene FGFR2 (10q26) and tumour suppressor genes PTEN/
MMAC1 (10q23) and DMBT1 (10q25-q26), both
involved in carcinogenesis, which could explain the
observation of both gains and losses of chromosomes 10
in gastric carcinomas [34-36]. Indeed chromosome 13
harbors tumour suppressor genes such as BRCA2
(13q12.3) and retinoblastoma gene (RB1) (13q14). In
contrast, gain of chromosome 13q has been correlated to
colorectal adenoma-to-carcinoma progression, and
amplification of chromosome 13 has been observed in
gastric adenomas with severe intraepithelial neoplasia
[14,37]. The precise role of chromosome 13 aberration in
gastric cancer therefore remains to be resolved.
Most frequent copy number gains were observed on chro-
mosomes 8, 9q, 11q and 20. Especially gains of chromo-
somes 8 and 20 are consistent with previous (array) CGH
studies in both gastric adenomas and gastric carcinomas
[13-16,19,25], implicating this as early events in tumour-
igenesis. Although gain of chromosome 11q has not been
described as a frequent event in adenomas, in carcinomas
gain or amplification on chromosome 11q is common
[13-16]. In the present study gain of chromosome 11q
was frequently observed in the adenomas, implying the
malignant potential of these adenomas.
Conclusion
These data indicate that gains on chromosomes 8, 9q, 11q
and 20 and losses on chromosomes 5q, 6, 10 and 13 are
early events in gastric carcinogenesis. Despite the pheno-
8 5q22.1-q23.2 13.28 RP11-276O18 RP11-14L4
6p12.3-q22.1 74.37 RP11-89l17 RP11-149M1
9p21.1-pter 31.18 RP11-147I11 RP11-12K1
10 133.18 RP11-10D13 RP11-45A17
13q14.3-q31.3 39.71 RP11-211J11 RP11-306O1
17 77.65 GS1-68F18 RP11-398J5
19 63.31 CTC-546C11 CTD-3138B18
20 60.87 RP4-686C3 RP4-591C20
22q 31.25 XX-bac32 CTA-722E9
9 5q14.3-q23.2 33.06 RP11-302L17 RP11-14L4
6p22.2-q22.3 8.44 RP11-91n3 RP11-88h24
6p12.1-q24.1 88.89 RP11-7h16 RP11-368P1
8 145.95 GS1-77L23 CTC-489D14
9q33.1-qter 13.60 RP11-91G7 GS1-135I17
10 133.18 RP11-10D13 RP11-45A17
11q23.3 3.16 RP11-4N9 RP11-215D10
13q14.3-qter 58.59 RP11-240M20 RP11-480K16
20q13.2-q13.31 1.96 RP11-55E1 RP5-832E24
21cen-q21.3 17.39 RP11-193B6 RP11-41N19
10 8q22.3-q23.3 12.93 RP11-142M8 RP11-143P23
10 134.52 RP11-10D13 RP11-122K13
13q21.1-q21.33 18.03 RP11-322F18 RP11-335N6
13q31.1-q31.3 8.99 RP11-533P8 RP11-505P2
11 - -
Table 1: Overview of the DNA copy number changes in 11 intestinal-type adenomas (Continued)Page 5 of 10
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Chromosomal aberrations Flanking clones
Tumour ID Gains Losses Segment size (Mb) Start End
12 1q21.3-q23.3 9.95 RP11-98D18 RP11-5K23
1q42.13-q43 14.07 RP11-375H24 RP11-80B9
3q 111.59 RP11-312H1 RP11-23M2
5q35.1-q35.3 9.11 RP11-20O22 RP11-451H23
6q 115.76 RP11-524H19 RP5-1086L22
7 156.09 RP11-510K8 RP11-518I12
17 77.48 RP11-4F24 RP11-313F15
20 63.47 CTB-106I1 CTB-81F12
13 - -
14 4 191.13 CTC-963K6 RP11-45F23
5q 128.59 CTD-2276O24 RP11-281O15
14q 83.81 RP11-98N22 RP11-73M18
16 89.71 RP11-344L6 RP4-597G12
20q13.2-q13.33 10.84 RP4-724E16 CTB-81F12
15 9q33.2-q34.3 16.81 RP11-57K1 RP11-83N9
11q23.2-q24.3 16.04 RP11-635F12 RP11-567M21
12q14.3-q15 2.58 RP11-30I11 RP11-444B24
20q13.31-q13.33 6.86 RP5-1153D9 RP5-963E22
22q 32.53 XX-p8708 CTA-722E9
16 9q33.3-qter 13.57 RP11-85C21 GS1-135I17
10p12.1-qter 110.28 RP11-379L21 RP11-45A17
11q23.1-q24.3 17.72 RP11-107P10 RP11-567M21
13q31.1-q32.1 10.84 RP11-661D17 RP11-40H10
20q13.2-q13.31 1.96 RP11-55E1 RP4-586J11
17 1p34.3-pter 35.59 RP1-37J18 RP11-204L3
1p33-qter 203.62 RP4-739H11 RP11-551G24
2q31.1-qter 66.00 RP11-205B19 RP11-556H17
5q21.1-q31.2 40.27 CTD-2068C11 RP11-515C16
5q31.3-qter 39.06 CTD-2323H12 RP11-451H23
6q 113.61 RP11-89D6 CTB-57H24
10 134.52 RP11-10D13 RP11-122K13
13q31.1-qter 36.14 RP11-388E20 RP11-245B11
20q13.2-qter 11.24 RP11-15M15 RP5-1022E24
18 5q11.2-q21.2 51.24 CTC-1329H14 RP1-66P19
6p12.1-q16.3 51.24 RP11-7H16 RP11-438N24
9pter-q13 66.82 GS1-41L13 RP11-265B8
10 133.04 RP11-10D13 RP11-45A17
13q21.1-q21.33 18.39 RP11-240M20 RP11-335N6
13q31.1-q31.3 12.45 RP11-551D9 RP11-100A3
21cen-q21.3 17.39 RP11-193B6 RP11-41N19
19 1p32.3-p21.1 50.40 RP11-117D22 RP5-1108M17
5q11.2-q13.3 24.64 RP4-592P18 CTD-2200O3
13q12.11-q14.3 31.58 RP11-187L3 RP11-327P2
15q12-q26.3 77.21 RP11-131I21 CTB-154P1
18q21.1-q23 31.31 RP11-46D1 RP11-154H12
22q13.2-qter 10.02 CTA-229A8 CTA-799F10
20 9p-q13 66.57 GS1-41L13 RP11-274B18
12q13.2-q21.1 (amplification) 19.50 RP11-548L8 RP11-255I14Page 6 of 10
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noma do not differ significantly at the level of DNA copy
number changes.
Methods
Material
Twenty-one paraffin-embedded gastric adenomas, 11
intestinal-type and 10 pyloric gland adenomas, were
included in this study (Figure 2A and 2B). Tumour and
patient data are given in Table 3. For each case, a tumour
area consisting for at least 70% of tumour cells was
demarcated on a 4 µm hematoxylin and eosin stained tis-
sue section. Adjacent 10–15 serial tissue sections of 10 µm
were stained with hematoxylin and the corresponding
tumour area was microdissected using a surgical blade. A
final 4µm "sandwich" section was made and stained with
hemotoxylin and eosin, to compare with the first slide as
a control. After deparaffinization, DNA was extracted by a
column-based method (QIAamp DNA mini kit; Qiagen,
Westburg, Leusden, NL) [38].
Genomic DNA obtained from peripheral blood from ten
normal individuals was pooled (either ten females or ten
males, depending on the gender of the patient from which
the adenoma was obtained) and used as control reference
DNA.
Array CGH
Array CGH was performed essentially as described previ-
ously [39]. Briefly, 300 ng tumour and reference DNAs,
sex-mismatch as experimental control, were labelled by
random priming (Bioprime DNA Labelling System, Invit-
rogen, Breda, NL), each in a volume of 50µL. Non incor-
porated nucleotides were removed using ProbeQuant G-
50 microcolumns (Amersham Biosciences). Cy3 labelled
test genomic DNA and Cy5 labelled reference DNA were
combined and co-precipitated with 100µg of human Cot-
1 DNA (Invitrogen, Breda, NL) by adding 0.1 volume of 3
M sodium acetate (pH 5.2) and 2.5 volumes of ice-cold
100% ethanol. The precipitate was collected by centrifuga-
tion at 14,000 rpm for 30 minutes at 4°C, and dissolved
in 130 µl hybridization mixture containing 50% forma-
mide, 2 × SCC and 4% SDS. The hybridization solution
was heated for 10 minutes at 73°C to denature the DNA,
followed by 60–120 minutes incubation at 37°C to allow
the Cot-1 DNA to block repetitive sequences. The mixture
was hybridized on an array containing approximately
5000 clones spotted in triplicate and spread along the
whole genome with an average resolution of 1.0 Mb. The
clones are comprised of the Sanger BAC clone set with an
average resolution along the whole genome of 1.0 Mb
[40], the OncoBac set [41], and selected clones of interest,
obtained from the Children's Hospital Oakland Research
Institute (CHORI). The selected clones comprise a collec-
tion of BAC clones on chromosome 6 filling the gaps
larger than 1 Mb, and full-coverage contigs on specific
regions on chromosomes 8, 13 and 20. Hybridization was
performed in a in a hybridization station (Hybstation12 –
Perkin Elmer Life Sciences, Zaventem, BE) and incubated
for 38 h at 37°C. After hybridization, slides were washed
in a solution containing 50% formamide, 2× SCC, pH 7
for 3 minutes at 45°C, followed by 1 minute wash steps at
room temperature with PN buffer (PN: 0.1 M sodium-
phosphate, 0.1% nonidet P40, pH 8), 0.2× SSC, 0.1× SCC
and 0.01× SCC.
12q21.2-qter 55.56 RP11-25J3 RP11-1K22
18q21.31-q23 23.28 RP11-383D22 CTC-964M9
20q13.13-q13.33 (amplification) 14.62 RP5-1041C10 RP5-1022E24
21 5p 43.15 CTD-2265D9 RP11-28I9
5q 130.26 RP11-269M20 RP11-451H23
6p 62.57 CTB-62I11 RP11-506N21
6q 106.73 RP11-767J14 RP5-1086L22
Table 2: Overview of the DNA copy number changes in 10 pyloric gland adenomas (Continued)
Comparison of DNA copy number alterations in intestinal and pyloric gland type gastric adenomasFigure 1
Comparison of DNA copy number alterations in intestinal 
and pyloric gland type gastric adenomas. A p-value (Y-axis) 
was calculated for every clone, based on a Wilcoxon test 
with ties, and plotted in chromosomal order from chromo-
some 1 to 22 (X-axis). Eight clones reached the level of sig-
nificance (p < 0.05), but failed to maintain a significantly low 
false discovery rate after correction for multiple comparison.Page 7 of 10
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Images of the arrays were acquired by scanning (Agilent
DNA Microarray scanner- Agilent technologies, Palo Alto,
USA) and quantification of the signal and background
intensities for each spot for the two channels Cy3 and Cy5
was performed by Imagene 5.6 software (Biodiscovery
Ltd, Marina del Rey, CA, USA). Local background was sub-
tracted from the signal median intensities and tumours to
reference ratios were calculated. The ratios were normal-
ized against the mode of the ratios of all autosomes.
Clones with poor quality of one of the triplicates and
hybridization with a standard deviation (SD) ≤ 0.22 and
clones with > 50% missing values in all adenomas were
excluded, leaving 4648 clones for further analysis. All sub-
sequent analyses were done considering the clone posi-
tion from the UCSC May2004 freeze of the Human
Golden Path.
Array CGH smooth [42,43], was used for automated
detection of breakpoints to determine copy number gains
and losses. Since variation in quality is observed in DNA
obtained from formalin-fixed paraffin-embedded gastric
tissues, different smoothing parameters were applied,
depending on the quality of the hybridization. For array
CGH profiles with a standard deviation smaller or equal
to 0.15, between 0.15 and 0.20 or between 0.20 and 0.22,
the applied smoothing parameters to determine gains and
losses were 0.10, 0.15 and 0.20 respectively. Log2 tumour
to reference ratio above 1 was regarded as amplification.
Statistical analysis
Unsupervised hierarchical cluster analysis was performed
to analyze the distributions of the genomic profiles of all
adenomas using TMEV software 3.0.3 [44]. Based on nor-
malized smoothed log2 tumour to normal fluorescence
intensity ratios, a hierarchical tree was constructed using
the parameters complete linkage and euclidean distance.
Pearson Chi-square test was used for analyzing correla-
tions between cluster membership and adenoma type
(SPSS 11.5.0 for windows, SPSS Inc, Chicago, IL, USA). P-
values less than 0.05 were considered to be significant.
Supervised analysis was used for identifying chromo-
somal regions specific for the two adenoma types using
CGH Multiarray and CGH Multiarray Region [45,46].
Based on normalized smoothed log2 tumour to normal
fluorescence intensity ratios, p-values were calculated for
the significance of difference of values for each clone
between pyloric gland and intestinal-type adenomas,
using a Wilcoxon test with ties. To correct for multiple
testing, a permutation-based false discovery rate (FDR)
was calculated [47].
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Haematoxilin and eosin staining (original magnification ×400) of intestina -type (A) a d pyloric gland (B) gastr  adenomasFigure 2
Haematoxilin and eosin staining (original magnification ×400) 
of intestinal-type (A) and pyloric gland (B) gastric adenomas. 
A. Intestinal-type adenoma of the stomach composed of 
irregularly arranged glands composed of intestinal-type epi-
thelium with eosinophilic cytoplasm and enlarged nuclei. B. 
Pyloric gland adenoma of the stomach composed of densely 
back to back packed glands consisting of cells with pale cyto-
plasm and small round hyperchromatic nuclei.
Table 3: Tumour and patient information
Tumour 
ID
Adenoma 
type
Grade of 
dysplasia
Gender Age Tumour 
ID
Adenoma 
type
Grade of 
dysplasie
Gender Age
1 Intestinal Moderate Male 75 12 Pyloric gland Moderate Male 78
2 Intestinal Moderate Male 45 13 Pyloric gland Mild Male 50
3 Intestinal Moderate Male 80 14 Pyloric gland Severe Female 76
4 Intestinal Moderate Male 79 15 Pyloric gland Moderate Female 85
5 Intestinal Moderate Male 76 16 Pyloric gland Moderate Male 63
6 Intestinal Moderate Male 75 17 Pyloric gland Mild Female 86
7 Intestinal Mild Male 57 18 Pyloric gland Moderate Female 59
8 Intestinal Moderate Male 64 19 Pyloric gland Moderate Male 69
9 Intestinal Mild Male 63 20 Pyloric gland Moderate Female 78
10 Intestinal Mild Male 75 21 Pyloric gland Moderate Male ?
11 Intestinal Moderate Female 45Page 8 of 10
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